Kester Kent Edward 4

What Happened

• Kester Kent Edward, a director of Turn Therapeutics (TTRX), received a derivative equity award covering 83,334 shares on 2026-06-04. The Form 4 reports the award at $0.00 per share (no cash paid at grant). This is an equity compensation grant (transaction code A), not a purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (filed within the two-business-day window).
• Award: 83,334 shares (derivative/option) reported at $0.00 per share.
• Shares owned after transaction: not specified in the provided summary—see the full Form 4 for total beneficial ownership.
• Footnote (F1): The option vests in 12 equal monthly installments on the last day of each month, beginning June 30, 2026, subject to continued service and the Issuer’s 2025 Omnibus Incentive Plan.
• Transaction code: A (award/grant).

Context

• This was a compensation grant (an option/derivative award) rather than an open-market purchase or sale; such awards are common for executives/directors and reflect pay, not an immediate buy/sell market signal.
• Vesting over 12 months means the shares/options will only become exercisable/owned if the director remains with the company and conditions of the plan are met.